FibroGen (FGEN) Appoints Michael Kauffman to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
June 9, 2025 4:02 PM EDTSAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.
Michael is a well-recognized biotech industry veteran, who brings a wealth of biotech leadership experience to our board, said James Schoeneck, chairman of the board of directors of FibroGen. His expertise spanning all stages of drug development will be invaluable as FibroGen progresses its pipeline. Michaels deep understanding of oncology will help the company through anticipated near-term clinical milestones and potential value-drivers.
FibroGen has differentiated potential... More
